Implementation and Uptake of Raltegravir Granules in Newborns Diagnosed With HIV Through Birth Testing in Maternity Settings in Zimbabwe During the COVID-19 Pandemic
- 20 March 2023
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 42 (7), 573-575
- https://doi.org/10.1097/inf.0000000000003906
Abstract
Zimbabwe introduced raltegravir (RAL) granules at 14 facilities providing point-of-care HIV birth testing, aiming to initiate all newborns with HIV on a RAL-based regimen. From June 2020 to July 2021, we tested 3172 of the 6989 (45%) newborns exposed to HIV; we diagnosed 59(2%) with HIV infection, of whom 27 (46%) initiated RAL. The SARS-CoV-2 coronavirus disease pandemic exacerbated supply chain and trained provider shortages, contributing to low birth testing, RAL uptake and 6-month viral load testing.Keywords
This publication has 5 references indexed in Scilit:
- Optimising neonatal antiretroviral therapy using raltegravir: a qualitative analysis of healthcare workers’ and caregivers’ perspectivesBMJ Paediatrics Open, 2022
- A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for UseThe Pediatric Infectious Disease Journal, 2021
- Impact of Routine Point-of-Care Versus Laboratory Testing for Early Infant Diagnosis of HIV: Results From a Multicountry Stepped-Wedge Cluster-Randomized Controlled TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2020
- Acceptability and Feasibility of Using Raltegravir Oral Granules for the Treatment of Neonates in a Low-resource SettingThe Pediatric Infectious Disease Journal, 2020
- Factors affecting acceptance of at-birth point of care HIV testing among providers and parents in Kenya: A qualitative studyPLOS ONE, 2019